MODERN ASPECTS OF MANAGEMENT OF PATIENTS WITH HELICOBACTER PYLORI-ASSOCIATED DISEASES: RECOMMENDATIONS OF THE EUROPEAN MAASTRICHT-V CONSENSUS
Prevention of gastric cancer is one of the main direction in the management of patients with Helicobacter pylori-associated diseases. Due to increasing resistance of H. pylori to antibiotics, quadrupletherapy with bismuth and concomitant therapy play central stage in the treatment of infection. Given the low resistance of H. pylori to clarithromycin, traditional triple therapy keeps meaning in Russia. Now it is proved that there are a lot of different microorganisms in the stomach that can influence the development of pathology. The use of probiotics helps to reduce the frequency of side effects and increases the effectiveness of H. pylori eradication.